Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on Lu AE58054 PK in Healthy Subjects
NCT02122692Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Mar 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Idalopirdine in Alzheimer's disease (AD), sponsored by Lundbeck. Primary endpoints: Area under the plasma concentration-time curve from time zero to 24 hours post-dose and Maximum observed plasma concentration at Day 11. Started Mar 2014; status: completed.
02
Drugs
Idalopirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02122692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02122692.